» Articles » PMID: 29188427

Recent Progress on Chikungunya Virus Research

Overview
Journal Virol Sin
Specialty Microbiology
Date 2017 Dec 1
PMID 29188427
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Chikungunya virus (CHIKV) is an arbovirus transmitted by Aedes mosquitos in tropical and subtropical regions across the world. After decades of sporadic outbreaks, it re-emerged in Africa, Asia, India Ocean and America suddenly, causing major regional epidemics recently and becoming a notable global health problem. Infection by CHIKV results in a spectrum of clinical diseases including an acute self-limiting febrile illness in most individuals, a chronic phase of recurrent join pain in a proportion of patients, and long-term arthralgia for months to years for the unfortunate few. No specific anti-viral drugs or licensed vaccines for CHIKV are available so far. A better understanding of virus-host interactions is essential for the development of therapeutics and vaccines. To this end, we reviewed the existing knowledge on CHIKV's epidemiology, clinical presentation, molecular virology, diagnostic approaches, host immune response, vaccine development, and available animal models. Such a comprehensive overview, we believe, will shed lights on the promises and challenges in CHIKV vaccine development.

Citing Articles

YBX1 is required for assembly of viral replication complexes of chikungunya virus and replication of multiple alphaviruses.

Li Z, Zhao L, Wang S, Hu C, Wang Y, Yang Y J Virol. 2025; 99(2):e0201524.

PMID: 39745458 PMC: 11852927. DOI: 10.1128/jvi.02015-24.


Host-adaptive mutations in Chikungunya virus genome.

Ning X, Xia B, Wang J, Gao R, Ren H Virulence. 2024; 15(1):2401985.

PMID: 39263937 PMC: 11404619. DOI: 10.1080/21505594.2024.2401985.


High seroprevalence of IgM antibodies against chikungunya among patients with acute febrile illness seeking healthcare in a malaria-endemic area in the Afar Region, Northeast Ethiopia.

Zerfu B, Kassa T, Mamo G, Larrick J, Legesse M SAGE Open Med. 2024; 12:20503121241276557.

PMID: 39263636 PMC: 11388298. DOI: 10.1177/20503121241276557.


In silico design and validation of a novel multi-epitope vaccine candidate against structural proteins of Chikungunya virus using comprehensive immunoinformatics analyses.

Mahmoodi S, Amirzakaria J, Ghasemian A PLoS One. 2023; 18(5):e0285177.

PMID: 37146081 PMC: 10162528. DOI: 10.1371/journal.pone.0285177.


Heart Disease and Arboviruses: A Systematic Review and Meta-Analysis.

Nicacio J, Gomes O, do Carmo R, Nunes S, Rocha J, de Souza C Viruses. 2022; 14(9).

PMID: 36146794 PMC: 9502577. DOI: 10.3390/v14091988.


References
1.
Erasmus J, Rossi S, Weaver S . Development of Vaccines for Chikungunya Fever. J Infect Dis. 2016; 214(suppl 5):S488-S496. PMC: 5137239. DOI: 10.1093/infdis/jiw271. View

2.
Hawman D, Stoermer K, Montgomery S, Pal P, Oko L, Diamond M . Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol. 2013; 87(24):13878-88. PMC: 3838294. DOI: 10.1128/JVI.02666-13. View

3.
Miner J, Cook L, Hong J, Smith A, Richner J, Shimak R . Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med. 2017; 9(375). PMC: 5448557. DOI: 10.1126/scitranslmed.aah3438. View

4.
Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G . French guidelines for the management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect. 2015; 45(7):243-63. DOI: 10.1016/j.medmal.2015.05.007. View

5.
Suhrbier A, Jaffar-Bandjee M, Gasque P . Arthritogenic alphaviruses--an overview. Nat Rev Rheumatol. 2012; 8(7):420-9. DOI: 10.1038/nrrheum.2012.64. View